The piece in question featured results from GW Pharmaceuticals PLC- ADR
and Greenwich Biosciences’ Phase 3 study of Epidiolex — an oral cannabidiol solution — in patients with treatment-resistant Lennox-Gastaut syndrome, or LGS, a rare form of childhood-onset epilepsy.
The reason why this announcement matters is Epidiolex’s potential to become the first in a new category of anti-epileptic drugs based on a pharmaceutical formulation of purified CBD, a non-psychoactive component present in marijuana, hemp and hops plants.
Per the study, 44 percent of patients using Epidiolex to treat highly treatment-resistant LGS exhibited a significant reduction in the frequency of drop seizures, a type of seizure that often results in the person falling down or “dropping.” The tolerability and safety profiles were in line with previous studies.
GW Pleased With ‘Breakthrough’ Results
“We are extremely pleased with the publication of the results from our Lennox-Gastaut study. This follows on the results from our Dravet syndrome study, which was published in the New England Journal of Medicine last year. It’s good to see the results of our studies published on the top level journals [of medicine],” Stephen Schultz, vice president of investor relations at GW Pharmaceuticals, told Benzinga. “I think all of this is an indication of how important the medical community sees these results as, how breakthrough they are.”
“We know that there is a lot going on in the cannabis field right now. Our goal is pretty focused, and that is to provide additional options to patients and to physicians who desire an FDA-approved pure CBD medicine,” Schultz said.
The Lancet http://www.thelancet.com